Knowledge clusterTransactional research — which medication is right for me?

Therapy-by-therapy intelligence

Side-by-side comparisons of GLP-1 and dual-agonist therapies — efficacy, mechanism, dosing, access, and trial data.

Last reviewed

In-depth answers

Topics in this cluster

  • Ozempic vs Wegovy
  • Semaglutide vs Tirzepatide
  • Mounjaro vs Zepbound
  • Brand vs compounded

How we compare

Every comparison page on GLP-1 Compare follows the same structure: a short, snippet-ready answer at the top, a head-to-head data table, a mechanism-of-action explainer, side-effect and cost analysis, and an FAQ block that mirrors how real patients ask the question.

We prioritize peer-reviewed clinical trials — the STEP program for semaglutide and SURMOUNT-1 for tirzepatide — over manufacturer marketing materials, and we cross-reference FDA drug labels so the AI assistants that surface our answers can verify them.

Frequently asked questions

Which GLP-1 medication produces the most weight loss?+

In direct phase III trial comparisons, tirzepatide (Mounjaro, Zepbound) has produced the largest mean total body weight loss — roughly 22.5% over 72 weeks at the 15 mg dose in SURMOUNT-1 — followed by semaglutide 2.4 mg (Wegovy) at roughly 15%.

Are Ozempic and Wegovy the same drug?+

Yes. Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly; Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg weekly.

Is compounded semaglutide as effective as branded versions?+

Compounded semaglutide is not FDA-approved, has not been studied in pivotal trials, and quality varies by pharmacy. Some patients report similar outcomes, but safety and consistency data lag the branded products.

Knowledge graph · related nodes

How this page connects to the rest of the GLP-1 knowledge base. Each link spans a different cluster — follow the one that maps to your next question.